(RYAN) Ryan Specialty Holdings - Overview
Sector: Financial Services | Industry: Insurance - Specialty | Exchange: NYSE (USA) | Market Cap: 8.872m USD | Total Return: -52.9% in 12m
Avg Turnover: 92.3M
EPS Trend: 97.9%
Qual. Beats: 1
Rev. Trend: 99.9%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Ryan Specialty Holdings, Inc. functions as a wholesale insurance brokerage and underwriting manager, facilitating the placement of complex risks for retail brokers and insurance carriers. The company operates through two primary channels: wholesale distribution and delegated authority, where it manages underwriting and product development on behalf of carriers.
As a specialist in the Excess and Surplus (E&S) market, the firm focuses on high-hazard or non-standard risks that traditional standard-market insurers typically decline. The wholesale brokerage model relies on deep technical expertise to secure coverage for commercial, industrial, and institutional clients across North America, Europe, and Asia.
Investors can further evaluate the companys valuation metrics and historical growth trends on ValueRay. This Chicago-based firm has expanded its global footprint since its founding in 2010 through both organic growth and strategic acquisitions within the fragmented specialty insurance sector.
- Hard market conditions drive higher premiums and increased wholesale brokerage commission revenue
- M&A execution and integration of specialty firms accelerate inorganic top-line growth
- Expansion of delegated authority underwriting capacity boosts high-margin program management fees
- Surplus lines market share gains capture complex risks shifting from standard carriers
- Wage inflation for specialized talent pressures operating margins and organic earnings growth
| Net Income: 131.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.66 > 1.0 |
| NWC/Revenue: 3.89% < 20% (prev 159.8%; Δ -155.9% < -1%) |
| CFO/TA 0.06 > 3% & CFO 619.1m > Net Income 131.6m |
| Net Debt (3.76b) to EBITDA (802.5m): 4.69 < 3 |
| Current Ratio: 1.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (129.6m) vs 12m ago 2.83% < -2% |
| Gross Margin: 67.56% > 18% (prev 0.40%; Δ 6.72k% > 0.5%) |
| Asset Turnover: 30.20% > 50% (prev 26.83%; Δ 3.37% > 0%) |
| Interest Coverage Ratio: 2.32 > 6 (EBITDA TTM 802.5m / Interest Expense TTM 221.6m) |
| A: 0.01 (Total Current Assets 5.58b - Total Current Liabilities 5.46b) / Total Assets 11.0b |
| B: 0.01 (Retained Earnings 120.5m / Total Assets 11.0b) |
| C: 0.05 (EBIT TTM 513.2m / Avg Total Assets 10.5b) |
| D: 0.01 (Book Value of Equity 130.2m / Total Liabilities 9.79b) |
| Altman-Z'' = 0.45 = B |
| DSRI: 0.11 (Receivables 565.3m/4.35b, Revenue 3.16b/2.65b) |
| GMI: 0.59 (GM 67.56% / 39.65%) |
| AQI: 0.93 (AQ_t 0.48 / AQ_t-1 0.51) |
| SGI: 1.19 (Revenue 3.16b / 2.65b) |
| TATA: -0.04 (NI 131.6m - CFO 619.1m) / TA 11.0b) |
| Beneish M = -4.09 (Cap -4..+1) = AAA |
As of May 28, 2026, the stock is trading at USD 32.71 with a total of 1,193,446 shares traded.
Over the past week, the price has changed by -3.14%,
over one month by -5.45%,
over three months by -16.53% and
over the past year by -52.89%.
Ryan Specialty Holdings has received a consensus analysts rating of 3.92. Therefore, it is recommended to buy RYAN.
- StrongBuy: 4
- Buy: 5
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 42.5 | 30% |
P/E Trailing = 40.9877
P/E Forward = 16.0256
P/S = 2.8608
P/B = 6.6504
Revenue TTM = 3.16b USD
EBIT TTM = 513.2m USD
EBITDA TTM = 802.5m USD
Long Term Debt = 3.53b USD (from longTermDebt, last quarter)
Short Term Debt = 62.6m USD (from shortTermDebt, last quarter)
Debt = 3.92b USD (from shortLongTermDebtTotal, last quarter) + Leases 173.4m
Net Debt = 3.76b USD (calculated: Debt 3.92b - CCE 154.7m)
Enterprise Value = 12.6b USD (8.87b + Debt 3.92b - CCE 154.7m)
Interest Coverage Ratio = 2.32 (Ebit TTM 513.2m / Interest Expense TTM 221.6m)
EV/FCF = 22.78x (Enterprise Value 12.6b / FCF TTM 554.6m)
FCF Yield = 4.39% (FCF TTM 554.6m / Enterprise Value 12.6b)
FCF Margin = 17.57% (FCF TTM 554.6m / Revenue TTM 3.16b)
Net Margin = 4.17% (Net Income TTM 131.6m / Revenue TTM 3.16b)
Gross Margin = 67.56% ((Revenue TTM 3.16b - Cost of Revenue TTM 1.02b) / Revenue TTM)
Gross Margin QoQ = 91.27% (prev 90.21%)
Tobins Q-Ratio = 1.15 (Enterprise Value 12.6b / Total Assets 11.0b)
Interest Expense / Debt = 5.66% (Interest Expense 221.6m / Debt 3.92b)
Taxrate = 13.82% (6.51m / 47.1m)
NOPAT = 442.3m (EBIT 513.2m * (1 - 13.82%))
Current Ratio = 1.02 (Total Current Assets 5.58b / Total Current Liabilities 5.46b)
Debt / Equity = 6.16 (Debt 3.92b / totalStockholderEquity, last quarter 636.2m)
Debt / EBITDA = 4.69 (Net Debt 3.76b / EBITDA 802.5m)
Debt / FCF = 6.78 (Net Debt 3.76b / FCF TTM 554.6m)
Total Stockholder Equity = 631.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.26% (Net Income 131.6m / Total Assets 11.0b)
RoE = 20.85% (Net Income TTM 131.6m / Total Stockholder Equity 631.2m)
RoCE = 12.32% (EBIT 513.2m / Capital Employed (Equity 631.2m + L.T.Debt 3.53b))
RoIC = 7.97% (NOPAT 442.3m / Invested Capital 5.55b)
WACC = 5.57% (E(8.87b)/V(12.8b) * Re(5.88%) + D(3.92b)/V(12.8b) * Rd(5.66%) * (1-Tc(0.14)))
Discount Rate = 5.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 33.33 | Cagr: 3.17%
[DCF] Terminal Value 77.97% ; FCFF base≈505.7m ; Y1≈579.8m ; Y5≈853.2m
[DCF] Fair Price = 70.12 (EV 12.8b - Net Debt 3.76b = Equity 9.08b / Shares 129.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.93 | EPS CAGR: 20.99% | SUE: 2.53 | # QB: 1
Revenue Correlation: 99.88 | Revenue CAGR: 21.32% | SUE: 1.06 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.60 | Chg30d=-17.20% | Revisions=-81% | Analysts=18
EPS next Quarter (2026-09-30): EPS=0.50 | Chg30d=-7.18% | Revisions=-70% | Analysts=18
EPS current Year (2026-12-31): EPS=2.04 | Chg30d=-8.17% | Revisions=-82% | GrowthEPS=+4.0% | GrowthRev=+6.9%
EPS next Year (2027-12-31): EPS=2.33 | Chg30d=-9.16% | Revisions=-81% | GrowthEPS=+14.3% | GrowthRev=+8.3%
[Analyst] Revisions Ratio: -82%